NCT07727902Not yet recruiting
Functional Inspiratory Muscle Training for Gait Recovery in Patients With Chronic Stroke
Effect of Functional Inspiratory Muscle Training on Spatiotemporal Gait Parameters in Patients With Chronic Stroke
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
The purpose of this randomized controlled trial is to evaluate the effect of functional inspiratory muscle training (F-IMT) on spatiotemporal gait parameters in patients with chronic stroke. Sixty participants with chronic stroke will be randomly assigned to either a functional inspiratory muscle training group or a conventional inspiratory muscle training group. Both groups will receive the same conventional rehabilitation program for 8 weeks. The primary outcome is spatiotemporal gait parameters measured using the STEADYS gait assessment system. Secondary outcomes include exercise capacity assessed by the Six-Minute Walk Test (6MWT) and health-related quality of life assessed using the EuroQol Five-Dimension (EQ-5D) questionnaire.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 16 Jul 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Cairo University
- Diseases
- Stroke
- NCT number
- NCT07727902
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 1 Aug 2026 to the primary completion date, 1 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous participation in inspiratory muscle training programs.
Other illness
- Unstable cardiovascular disease (e.g., recent myocardial infarction, uncontrolled hypertension, decompensated heart failure).
- Uncontrolled metabolic disease or poorly controlled diabetes mellitus.
- Severe pulmonary disease or respiratory impairment (e.g., severe COPD, hypoxemia, chronic cough, or sputum retention).
- Active malignancy.
- Presence of nasal feeding tube, tracheostomy tube, or any condition preventing implementation of the study procedures.
- Severe musculoskeletal disorders affecting gait performance (e.g., lower limb fracture, severe osteoarthritis, or amputation).
- Significant cognitive or communication impairment preventing reliable participation.
- Other neurological disorders affecting gait (e.g., Parkinson's disease, multiple sclerosis, spinal cord injury).
Other
- Severe spasticity (Modified Ashworth Scale \>3) or fixed contractures.
- Severe obesity (BMI ≥35 kg/m²) that may interfere with gait assessment or exercise performance.
Who the study is looking for
- Patients aged between 55 and 65 years.
- Both male and female participants.
- Chronic stroke patients (\>6 months after stroke onset), including ischemic or hemorrhagic stroke confirmed by neuroimaging.
- Moderate gait impairment with gait speed ranging from 0.4 to 0.8 m/s.
- Ability to understand instructions and communicate sufficiently to participate in the study procedures.
- Breathing spontaneously without ventilatory support.
- No thoracic or abdominal surgery within the previous 6 months.
- No facial palsy, or mild facial palsy without limitation of labial occlusion.
- Ability to walk independently for at least 10 meters with or without an assistive device.
- Willingness to participate and provide written informed consent.
Age in the registry: 55 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.